SCHEMBL13043249

SCHEMBL13043249

Cc1ccc(-c2nc3ncnc(N)c3nc2-c2ccc(O)c(O)c2)cc1O

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 14/20 0.85
PIK3CD O00329 6/20 0.51
ABL1 P00519 5/20 0.51
EGFR P00533 5/20 0.51
PIK3CA P42336 5/20 0.51
PIK3CB P42338 5/20 0.51
MTOR P42345 5/20 0.51
PI4KB Q9UBF8 5/20 0.51
HCK P08631 4/20 0.51
SRC P12931 4/20 0.51
KDR P35968 4/20 0.51
EPHB4 P54760 4/20 0.51
PRKDC P78527 4/20 0.51
ADK P55263 1/20 0.49
BTK Q06187 1/20 0.42
JAK3 P52333 1/20 0.42
PIK3C2B O00750 1/20 0.39
PDXK O00764 1/20 0.39
GAK O14976 1/20 0.39
MAP3K7 O43318 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3533560 0.92 PIK3CG (1.00) PIK3CGPIK3CDABL1EGFRPIK3CA
Hydrochloric Acid SCHEMBL3536157 0.91 PIK3CG (0.97) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL13927979 0.87 PIK3CG (0.89) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL3732209 0.86 PIK3CG (0.82) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL13043247 0.83 PIK3CG (0.84) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL3536162 0.80 PIK3CG (0.75) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL3745443 0.79 PIK3CG (0.70) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL3745440 0.79 PIK3CG (0.70) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL3532692 0.76 PIK3CG (1.00) PIK3CGPIK3CDABL1EGFRPIK3CA
SCHEMBL13019024 0.76 PIK3CG (0.86) PIK3CGPIK3CDABL1EGFRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100278811-A1 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF TARGEGEN INC. 2010-11-04 US disclosed
US-20070208019-A1 Vasculostatic agents and methods of use thereof TARGEGEN, INC. 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208019-A1 Vasculostatic agents and methods of use thereof RBP1, RBP4, VCAM1 PIK3CG 2378/4885PIK3CD 3513/4885ABL1 4387/4885
US-20100278811-A1 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF RBP1, RBP4, VCAM1 PIK3CG 2378/4885PIK3CD 3513/4885ABL1 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.